On Tuesday, Pfizer announced a $2.00 billion deal with the US government for its Covid-19 antiviral treatment Paxlovid.
Under the agreement, the New York-based firm will provide an additional 3.70 million courses to the United States in early 2020.
Previously, the administration paid around $530.00 per treatment or about $10.60 billion for 20 million courses. In the latest contract, they will give the same amount.
Last year, Pfizer announced that it could produce 120 million Paxlovid treatments in 2022.
Then in December, the US drug administration allowed people ages 12 and older to undergo the therapy.
Generally, the medication has proven that it could reduce the risk of hospitalization and death of unvaccinated patients from Covid-19.
Moreover, the clinical trial results show that it could be effective even for those who have already been vaccinated.
Currently, Pfizer stated that it has sold around 37 million courses globally, including 20 million in the United States.
Furthermore, the treatment is available for free in the West.
Additionally, data from the Us government revealed that 9 million courses had been delivered to pharmacies, 6 million of which have already been used.
Separately, analysts projected that Paxlovid sales would reach $22 billion in 2022.
FDA Granted Pfizer’s Vaccine Priority Review
Recently, Pfizer revealed that the FDA had granted its respiratory syncytial vaccine a priority review.
Due to this, it has shortened the evaluation period to be around 4 months.
In its trial, the treatment showed a single dose efficacy and safety for adults aged 66 years or older.
In particular, it demonstrated 66.70% potency in combating respiratory syncytial virus (RSV).
Likewise, it displayed an 85.70% success rate in fighting severe RSV-associated lower respiratory tract illness.
In addition, the Centers for Disease Control and Prevention (CDC) predicted that the vaccine could help prevent around 120,000 hospitalization and 10,000 deaths in the US each year.
Looking forward, the FDA is anticipated to release its decision in May 2023.
